Clinical trials: Medically Resistant Seizures
Epilepsy, Partial Seizure
RNS System RESPONSE Study
To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.
- Conditions
- Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy
- Trial name
- RESPONSE (NCT04839601)
- Testing
- RNS System
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- NeuroPace
Status Epilepticus, Seizure
Ketogenic Diet for Refractory Status Epilepticus
This research is being done to observe the safety, tolerability, side effects, and effectiveness of the ketogenic diet in people with continuous seizures (status epilepticus) being treated in a neurointensive care unit.
- Conditions
- Status Epilepticus, Seizure, Epilepsy, Refractory Status Epilepticus
- Trial name
- NCT01796574
- Testing
- Ketogenic diet
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins University
Epilepsy, Seizure
Modified Atkins Diet Plus KetoCal for Adult Epilepsy
The modified Atkins diet (MAD) has been shown to be effective in treating children and adults with medically resistant seizures.
- Conditions
- Epilepsy, Seizure, Medically Resistant Epilepsy, Medically Resistant Seizures
- Trial name
- NCT01834482
- Testing
- Modified Atkins diet, KetoCal
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Johns Hopkins University
Epilepsy, Seizure
Medium Chain Triglycerides as an Adjunct to the Modified Atkins Diet for Women With Catamenial Epilepsy
The modified Atkins diet (MAD) has been shown to be effective in treating intractable epilepsy. Approximately 55% of the patients started on the diet are women of childbearing age and women with epilepsy often have a pattern of…
- Conditions
- Epilepsy, Seizure, Catamenial Epilepsy, Medically Resistant Epilepsy
- Trial name
- NCT02426047
- Testing
- betaquik®
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Johns Hopkins University
Epilepsy
Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy
Part A: To evaluate the safety and tolerability of multiple ascending doses of GWP42003-P compared with placebo with respect to: Incidence, type and severity of adverse events (AEs) Effect on vital signs, including weight Effect…
- Trial name
- NCT02286986
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Utah